Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial
Abstract
Advanced biliary tract cancer (BTC) has a poor prognosis, even after combined chemotherapy of gemcitabine and oxaliplatin (GEMOX). To investigate the efficacy and safety of GEMOX chemotherapy combining atezolizumab and bevacizumab in advanced BTC, the authors designed an open-label, single-arm, phase II clinical trial and will enroll patients with stage IV BTC. The participants will receive GEMOX chemotherapy combined with atezolizumab plus bevacizumab. The primary end point is objective response rate; the secondary end points are overall survival, disease control rate, progression-free survival, time to progression, duration of response and safety. The results of this trial are expected to provide novel, safe and effective treatment options for patients with advanced BTC, which could further improve their prognosis.
Clinical Trial Registration: ChiCTR2100049830 (ChiCTR.org).
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 21(1), e29–e41 (2020).
- 2. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 5(12), 1749–1768 (2019).
- 3. . Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology 136(4), 1134–1144 (2009).
- 4. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362(14), 1273–1281 (2010). •• Gemcitabine and cisplatin or oxaliplatin was the standard first-line treatment for advanced biliary tract cancer, though the response was unsatisfactory.
- 5. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann. Oncol. 15(9), 1339–1343 (2004). •• Gemcitabine and cisplatin or oxaliplatin was the standard first-line treatment for advanced biliary tract cancer, though the response was unsatisfactory.
- 6. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol. 16(8), 967–978 (2015). • The combination of antiangiogenic agents and chemotherapy might be a treatment strategy for advanced biliary tract cancers.
- 7. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. Lancet Oncol. 22(10), 1468–1482 (2021). • The combination of antiangiogenic agents and chemotherapy might be a treatment strategy for advanced biliary tract cancers.
- 8. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 86, 102017 (2020).
- 9. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 11(1), 48–54 (2010).
- 10. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J. Immunother. Cancer 8(2), e001240 (2020).
- 11. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 6(6), 888–894 (2020).
- 12. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. J. Immunother. Cancer 8(1), e000367 (2020).
- 13. A phase II study of pembrolizumab in combination with capecitabine and oxaliplatin with molecular profiling in patients with advanced biliary tract carcinoma. Oncologist 27(3), e273–e285 (2022).
- 14. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J. Clin. Oncol. 40(Suppl. 4), S378 (2022). • The combination of immunotherapy and chemotherapy demonstrated promising antitumor activity in advanced biliary tract cancers.
- 15. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382(20), 1894–1905 (2020).
- 16. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 19(5), 541–565 (2021).
- 17. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer Med. 3(6), 1502–1511 (2014).
- 18. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther. Adv. Med. Oncol. 13, 17588359211036544 (2021).